At the news
? NEUTRALIMPACT 2/10 3 filed Apr 24, 2026 at 16:15 ET
Matthew Gall, CFO of Tango Therapeutics, filed a Form 3 and granted a power of attorney to Julie Fogarty to file SEC reports on his behalf, including Forms 3, 4, and 5. This is a routine compliance filing related to insider reporting obligations.
- Matthew Gall, CFO of Tango Therapeutics, filed a Form 3 indicating initial beneficial ownership reporting.
- He granted power of attorney to Julie Fogarty to file Forms 3, 4, and 5, Schedule 13D/G, and amendments on his behalf.
- The filing was made effective as of April 24, 2026, with a report date of April 15, 2026.
- No transaction or change in beneficial ownership was disclosed; this is an administrative filing.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access